NCT07604467Active, not recruiting
The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome
Effects of CD34+ Stem Cells on Left Ventricular Dysfunction Among Patients With Takotsubo Syndrome
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 17 May 2026
- Start date
- 6 Sept 2021
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- University Medical Centre Ljubljana
- Diseases
- Heart failure
- NCT number
- NCT07604467
What you commit to
- Study type: Observational
- Planned participants: 40
- From 6 Sept 2021 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Other concurrent cardiomyopathies
- Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event
- Previous interventional coronary artery procedure in the last 6 months before TTS acute event
- Patients receiving immunosuppressive therapy
Other illness
- Ischemic heart disease with at least one complete total occlusion
- obstructive coronary artery disease
- Significant valvular heart disease
- Significant peripheral artery occlusive disease
- Active or remitted hematologic malignancy
- Significant comorbiditeis affecting patients survival (malignancy)
- Failure to obtain freely given, informed consent form.
Age
- Patients under the age of 18 years
Other
- Active infectious myocarditis
Who the study is looking for
- Minimum age 18 years
- Established TTS per InterTak registry criteria
- Signed consent form
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Advanced Heart Failure and Transplantation Program, Department of Cardiology, UMC Ljubljana, Slovenia Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.